A new research has found that circulating tumour cells are associated with poorer survival in pancreatic cancer patients.
The study, conducted by researchers at the Fox Chase Cancer Center, also uncovered evidence that not all circulating tumour cells are the same, and some may predict worse outcomes than others.
Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
"This is one of the first studies looking at the role of circulating tumour cells in pancreatic cancer."
Previous work has demonstrated that prostate, colon, or breast cancer patients who have more circulating tumour cells have poorer survival than patients with fewer circulating tumour cells.
Researchers Study Methods to Preventing Pancreatic Islet Loss Post Transplantation
Although transplantation of pancreatic islets is an attractive way to treat type 1 diabetes, early islet loss soon after transplantation has limited its clinical use.
Although transplantation of pancreatic islets is an attractive way to treat type 1 diabetes, early islet loss soon after transplantation has limited its clinical use.
The team used an immunomagnetic separation system to isolate circulating tumour cells from patients' blood at three time points.
Advertisement
Pancreatic Tumor Aggressiveness can be Predicted by Blood-Flow Metabolism Mismatch
A blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness has been identified by researchers from Turku, Finland.
A blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness has been identified by researchers from Turku, Finland.
The team found that 50 per cent of the patients had one or more circulating tumour cell per 7.5 mL peripheral blood at baseline.
Advertisement
Use of Swedish 'snus' is Linked to a Doubled Risk of Pancreatic Cancer
People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas.
People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas.
Moreover, the presence of circulating tumour cells correlated with patient outcomes.
Patients with circulating tumour cells at study entry had a median overall survival of 191 days compared with 269 days for those without circulating tumour cells, although the difference did not reach statistical significance in the small study population.
A similar trend appeared for progression-free survival, with a median of 85 days for those with detectable circulating tumour cells compared with 137 days for those without.
Patients who had circulating tumour cells at either point after therapy initiation also trended towards poorer overall or progression-free survival.
Interestingly, the investigators found that some circulating tumour cells may be worse than others.
Patients whose circulating tumour cells expressed the MUC1 protein, which has been associated with more aggressive pancreatic cancer, trended towards a shorter median overall survival than those whose circulating tumour cells did not express the protein, at 85.5 and 310 days, respectively.
Negin said: "We find that having circulating tumour cells is bad.
"But the more interesting story that appears to be coming out of our study is that not all circulating tumour cells are equal. The MUC1 cells seem particularly bad, suggesting that there is a difference in the biology of these tumours and providing some insight into how these tumours function."
Negin will present the study at the 46th Annual Meeting of the American Society of Clinical Oncology on June 6.
Source-ANI
RAS
